2021 SITC临床实践指南：乳腺癌的免疫治疗

2021-08-09 肿瘤免疫治疗学会 J Immunother Cancer.2021 Aug;9(8):e002597.

乳腺癌在历史上一直是一种在很大程度上无法获得免疫疗法的疾病。最近，免疫检查点抑制剂 (ICIs) 联合化疗治疗晚期/转移性三阴性乳腺癌 (TNBC) 已证明有效，包括更长的无进展生存期和提高部分患者的

中文标题：

英文标题：

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer

发布机构：

肿瘤免疫治疗学会

发布日期：

2021-08-09

简要介绍：

乳腺癌在历史上一直是一种在很大程度上无法获得免疫疗法的疾病。最近，免疫检查点抑制剂 (ICIs) 联合化疗治疗晚期/转移性三阴性乳腺癌 (TNBC) 已证明有效，包括更长的无进展生存期和提高部分患者的总生存期。基于随机试验的临床获益，美国（美国）食品和药物管理局 (FDA) 已批准 ICI 联合化疗治疗某些晚期/转移性 TNBC 患者，扩大了患者的选择范围。然而，关于免疫治疗的最佳化疗主干、基于生物标志物的适当治疗患者选择、早期疾病免疫治疗的最佳策略以及在除 TNBC 之外的组织学亚型中的潜在用途等方面的问题仍然存在。为了就这些和其他重要问题向肿瘤学界提供指导，癌症免疫治疗学会 (SITC) 召集了一个多学科专家小组来制定临床实践指南 (CPG)。专家小组借鉴已发表的文献及其临床经验，就乳腺癌免疫治疗的这些重要方面为医疗保健专业人员制定建议，包括诊断测试、治疗计划、免疫相关不良事件 (irAE) 和患者质量生活 (QOL) 方面的考虑。本 CPG 中基于证据和基于共识的建议旨在为治疗乳腺癌患者的癌症护理提供者提供指导。

相关资料下载：

GetToolGuiderByIdResponse(projectId=1, id=f99541c002165691, title=2021 SITC临床实践指南：乳腺癌的免疫治疗, enTitle=Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer, guiderFrom=J Immunother Cancer.2021 Aug;9(8):e002597., authorId=0, author=, summary=乳腺癌在历史上一直是一种在很大程度上无法获得免疫疗法的疾病。最近，免疫检查点抑制剂 (ICIs) 联合化疗治疗晚期/转移性三阴性乳腺癌 (TNBC) 已证明有效，包括更长的无进展生存期和提高部分患者的, cover=https://img.medsci.cn/2021829/1630244484661_2020535.jpg, journalId=0, articlesId=null, associationId=1167, associationName=肿瘤免疫治疗学会, associationIntro=null, copyright=0, guiderPublishedTime=Mon Aug 09 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="bp3-card bp3-elevation-0 result-block" style="color: #182026;"> <div class="bp3-collapse"> <div class="bp3-collapse-body bp3-fixed-positioning-containing-block" aria-hidden="false"> <div class="common-result"> <div class="general-result"> <p>乳腺癌在历史上一直是一种在很大程度上无法获得免疫疗法的疾病。最近，免疫检查点抑制剂 (ICIs) 联合化疗治疗晚期/转移性三阴性乳腺癌 (TNBC) 已证明有效，包括更长的无进展生存期和提高部分患者的总生存期。基于随机试验的临床获益，美国（美国）食品和药物管理局 (FDA) 已批准 ICI 联合化疗治疗某些晚期/转移性 TNBC 患者，扩大了患者的选择范围。然而，关于免疫治疗的最佳化疗主干、基于生物标志物的适当治疗患者选择、早期疾病免疫治疗的最佳策略以及在除 TNBC 之外的组织学亚型中的潜在用途等方面的问题仍然存在。为了就这些和其他重要问题向肿瘤学界提供指导，癌症免疫治疗学会 (SITC) 召集了一个多学科专家小组来制定临床实践指南 (CPG)。专家小组借鉴已发表的文献及其临床经验，就乳腺癌免疫治疗的这些重要方面为医疗保健专业人员制定建议，包括诊断测试、治疗计划、免疫相关不良事件 (irAE) 和患者质量生活 (QOL) 方面的考虑。本 CPG 中基于证据和基于共识的建议旨在为治疗乳腺癌患者的癌症护理提供者提供指导。</p> </div> </div> </div> </div> </div>, tagList=[TagDto(tagId=285, tagName=乳腺癌)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=89, categoryName=乳腺癌, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=285, guiderKeyword=乳腺癌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=4, opened=0, paymentType=, paymentAmount=2, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=9591, appHits=194, showAppHits=0, pcHits=875, showPcHits=9396, likes=0, shares=7, comments=5, approvalStatus=1, publishedTime=Sun Aug 29 22:36:14 CST 2021, publishedTimeString=2021-08-09, pcVisible=1, appVisible=1, editorId=1614372, editor=MedSciZeng, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=qiushida2, createdTime=Sun Aug 29 21:41:33 CST 2021, updatedBy=1614372, updatedName=MedSciZeng, updatedTime=Sat Jan 06 06:07:38 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 SITC临床实践指南：乳腺癌的免疫治疗.pdf)])

2021 SITC临床实践指南：乳腺癌的免疫治疗.pdf

下载请点击：

评论区 (5)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1225353, encodeId=bf6b12253530d, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220718/40f20a20ac39449bb9b54f0a56b3bd59/badab63a8f8940b1aa22f908b6cb9dc4.jpg, createdBy=5b9f6414712, createdName=ms5000000275821148, createdTime=Thu Jun 09 07:37:43 CST 2022, time=2022-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179367, encodeId=c74311e936767, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f9b5676168, createdName=zhangfan5297, createdTime=Fri Dec 31 16:47:37 CST 2021, time=2021-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085792, encodeId=35cb1085e929a, content=一起学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98ad6192838, createdName=66304_9712, createdTime=Thu Dec 30 12:53:50 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060127, encodeId=4380106012e0b, content=一起学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d16d2301166, createdName=旭日东升a, createdTime=Wed Oct 13 14:15:46 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056362, encodeId=1eb8105636212, content=积分太少了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJghY6kJrb4qteTcWjQMJmlzUFjdTITxVPA88U3EicxFQoiaVS51iaXavp0Yia84bKDdYnC6XpOYic7n9w/132, createdBy=d8ef2246210, createdName=Icefirefox, createdTime=Thu Sep 30 07:53:22 CST 2021, time=2021-09-30, status=1, ipAttribution=)]
2022-06-09 ms5000000275821148

学习了

80 0
[GetPortalCommentsPageByObjectIdResponse(id=1225353, encodeId=bf6b12253530d, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220718/40f20a20ac39449bb9b54f0a56b3bd59/badab63a8f8940b1aa22f908b6cb9dc4.jpg, createdBy=5b9f6414712, createdName=ms5000000275821148, createdTime=Thu Jun 09 07:37:43 CST 2022, time=2022-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179367, encodeId=c74311e936767, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f9b5676168, createdName=zhangfan5297, createdTime=Fri Dec 31 16:47:37 CST 2021, time=2021-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085792, encodeId=35cb1085e929a, content=一起学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98ad6192838, createdName=66304_9712, createdTime=Thu Dec 30 12:53:50 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060127, encodeId=4380106012e0b, content=一起学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d16d2301166, createdName=旭日东升a, createdTime=Wed Oct 13 14:15:46 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056362, encodeId=1eb8105636212, content=积分太少了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJghY6kJrb4qteTcWjQMJmlzUFjdTITxVPA88U3EicxFQoiaVS51iaXavp0Yia84bKDdYnC6XpOYic7n9w/132, createdBy=d8ef2246210, createdName=Icefirefox, createdTime=Thu Sep 30 07:53:22 CST 2021, time=2021-09-30, status=1, ipAttribution=)]
2021-12-31 zhangfan5297

学习了

128 0
[GetPortalCommentsPageByObjectIdResponse(id=1225353, encodeId=bf6b12253530d, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220718/40f20a20ac39449bb9b54f0a56b3bd59/badab63a8f8940b1aa22f908b6cb9dc4.jpg, createdBy=5b9f6414712, createdName=ms5000000275821148, createdTime=Thu Jun 09 07:37:43 CST 2022, time=2022-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179367, encodeId=c74311e936767, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f9b5676168, createdName=zhangfan5297, createdTime=Fri Dec 31 16:47:37 CST 2021, time=2021-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085792, encodeId=35cb1085e929a, content=一起学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98ad6192838, createdName=66304_9712, createdTime=Thu Dec 30 12:53:50 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060127, encodeId=4380106012e0b, content=一起学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d16d2301166, createdName=旭日东升a, createdTime=Wed Oct 13 14:15:46 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056362, encodeId=1eb8105636212, content=积分太少了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJghY6kJrb4qteTcWjQMJmlzUFjdTITxVPA88U3EicxFQoiaVS51iaXavp0Yia84bKDdYnC6XpOYic7n9w/132, createdBy=d8ef2246210, createdName=Icefirefox, createdTime=Thu Sep 30 07:53:22 CST 2021, time=2021-09-30, status=1, ipAttribution=)]
2021-12-30 66304_9712

一起学习

85 0
[GetPortalCommentsPageByObjectIdResponse(id=1225353, encodeId=bf6b12253530d, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220718/40f20a20ac39449bb9b54f0a56b3bd59/badab63a8f8940b1aa22f908b6cb9dc4.jpg, createdBy=5b9f6414712, createdName=ms5000000275821148, createdTime=Thu Jun 09 07:37:43 CST 2022, time=2022-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179367, encodeId=c74311e936767, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f9b5676168, createdName=zhangfan5297, createdTime=Fri Dec 31 16:47:37 CST 2021, time=2021-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085792, encodeId=35cb1085e929a, content=一起学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98ad6192838, createdName=66304_9712, createdTime=Thu Dec 30 12:53:50 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060127, encodeId=4380106012e0b, content=一起学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d16d2301166, createdName=旭日东升a, createdTime=Wed Oct 13 14:15:46 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056362, encodeId=1eb8105636212, content=积分太少了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJghY6kJrb4qteTcWjQMJmlzUFjdTITxVPA88U3EicxFQoiaVS51iaXavp0Yia84bKDdYnC6XpOYic7n9w/132, createdBy=d8ef2246210, createdName=Icefirefox, createdTime=Thu Sep 30 07:53:22 CST 2021, time=2021-09-30, status=1, ipAttribution=)]
2021-10-13 旭日东升a

一起学习

123 0
[GetPortalCommentsPageByObjectIdResponse(id=1225353, encodeId=bf6b12253530d, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220718/40f20a20ac39449bb9b54f0a56b3bd59/badab63a8f8940b1aa22f908b6cb9dc4.jpg, createdBy=5b9f6414712, createdName=ms5000000275821148, createdTime=Thu Jun 09 07:37:43 CST 2022, time=2022-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179367, encodeId=c74311e936767, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f9b5676168, createdName=zhangfan5297, createdTime=Fri Dec 31 16:47:37 CST 2021, time=2021-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085792, encodeId=35cb1085e929a, content=一起学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98ad6192838, createdName=66304_9712, createdTime=Thu Dec 30 12:53:50 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060127, encodeId=4380106012e0b, content=一起学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d16d2301166, createdName=旭日东升a, createdTime=Wed Oct 13 14:15:46 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056362, encodeId=1eb8105636212, content=积分太少了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJghY6kJrb4qteTcWjQMJmlzUFjdTITxVPA88U3EicxFQoiaVS51iaXavp0Yia84bKDdYnC6XpOYic7n9w/132, createdBy=d8ef2246210, createdName=Icefirefox, createdTime=Thu Sep 30 07:53:22 CST 2021, time=2021-09-30, status=1, ipAttribution=)]
2021-09-30 Icefirefox

积分太少了

109 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

肿瘤科指南

2021 SITC临床实践指南：乳腺癌的免疫治疗

相关指南

拓展阅读

科室

工具

服务